Abstract:Abstract Abstract 193FN2 INTRODUCTION: aHUS is a genetic, systemic disease with a devastating prognosis caused by chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA), progressive organ damage and premature mortality. In a 26-wk phase II trial, pts receiving ECU, a terminal complement inhibitor, had a highly significant increase in platelet count (a measure of TMA improvement) (primary endpoint: 73×109/L increase; p=0.0001). 13/15 pts with low platelet count at baseline (BL) (ITT) had platelet normalization at Wk 26. 15/17 pts (88%) achieved TMA event-free status (≥12 wks of stable platelet count, no PE/PI and no new dialysis). 13/13 pts treated with ECU for 26 wks had platelet normalization at Wk 26 and 15/15 treated with ECU for 26 wks achieved TMA event-free status. Median TMA intervention rate was 0 (no. of PE/PI and new dialysis events/pt/day). Importantly, 4/5 pts on dialysis with PE/PI discontinued dialysis with ECU. ECU was well tolerated (Legendre. ASN 2010). We report longer follow-up data from the extension phase of this ongoing trial. METHODS: Pts ≥12 yrs with aHUS and persistent TMA despite ≥4 PE/PI sessions 1 wk before screening were enrolled in a 26-wk, controlled, open-label, single-arm phase II trial and continued into an extension trial. ECU dosage: 900mg/wk for 4 wks, 1200mg at Wk 5, 1200mg q2 wks. All pts received a meningococcal vaccine and prophylactic antibiotics ≥14 days after vaccination. Efficacy analyses were based on ITT population. RESULTS: 17 pts enrolled (2 discontinued at Wks 1 and 6; systemic lupus erythematosus [protocol violation] and an adverse event unrelated to ECU, respectively). Median time from diagnosis to screening=10mo (0.3–236). Median duration from overt clinical manifestations of aHUS to screening=0.75mo (0.2–4). Median number of PE/PI sessions per pt during aHUS current clinical presentation=17 (2–37). 5 patients (29%) required dialysis at baseline. Median age=28 yrs. 4 pts (24%) had no identified complement regulatory factor mutations (CRFM). ECU mean (SD) duration=58 (29) wks at data cut-off. Mean change (SD) in platelet count from BL was maintained (97×109/L [81] at Wk 26 vs 98×109/L [60] at 1 yr). All 13 pts who had platelet normalization at Wk 26 continued to maintain normal levels at data cut-off. The same 15/17 (88%) pts achieved TMA event-free status at data cut-off. All pts receiving sustained ECU treatment throughout the study achieved TMA event-free status at data cut-off. Renal function was maintained and continued to further improve in pts with ongoing ECU: improvement ≥1 CKD stage from BL: from 10 (59%) pts at Wk 26 to 11 (65%) pts at data cut-off and ≥25% decrease in creatinine from BL: from 11 (65%) pts at Wk 26 to 13 (77%) pts at data cut-off. With sustained ECU therapy, only 1 of the 5 pts at baseline continued on to require dialysis and no patient newly required dialysis (as of data cut off). Long-term chronic ECU was similarly effective in pts with/without identified CRFM. ECU was generally well tolerated; adverse events deemed related to ECU were reported in 12 pts (mostly mild to moderate, 1 severe). The extension trial continues. CONCLUSIONS: In aHUS, despite PE/PI, >50% of pts either die, require dialysis, or have permanent renal damage within the first year of diagnosis. In contrast, all pts treated with ECU for a mean duration of >1 yr remain alive, 4 out of 5 pts became dialysis free, and no pt newly required dialysis. This demonstrates that continued ECU treatment significantly transformed the clinical course of aHUS in this pt population. In addition, long-term ECU therapy suppressed TMA and dramatically improved renal function. These long-term follow-up data further strengthen the evidence for ECU as the new standard of care for aHUS. Disclosures: Greenbaum: Alexion: Consultancy, Honoraria, Research Funding, Speakers Bureau. Off Label Use: Eculizumab for the treatment of atypical hemolytic syndrome as part of clinical trials. Babu:Alexion: Research Funding. Furman:Alexion: Research Funding. Sheerin:Alexion: Research Funding. Cohen:Alexion: Research Funding. Gaber:Alexion: Research Funding. Delmas:Alexion: Research Funding. Loirat:Alexion: Research Funding. Bedrosian:Alexion: Employment. Legendre:Alexion: Research Funding.

Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome

Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses

Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody-mediated hemolytic uremic syndrome

Efficacy of cascade plasmapheresis in comparison with conventional therapeutic plasma exchange for relapsed atypical hemolytic uremic syndrome: A case report

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Plasma Exchange Combined Continuous Veno-Venous Hemo Diafiltration in the Treatment of Critical Hemolytic Uremic Syndrome

Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study

Comparison of efficacy and safety of different anticoagulation regimens in plasma exchange: A systematic review and meta-analysis

Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease

Plasma exchange does not improve overall survival in patients with acute liver failure in a real world cohort

Plasma Exchange As an Adjunctive Therapy for Crescentic IgA Nephropathy.

Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts' perspectives with associated cost-consequence analysis

Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance

Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes

A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX)

Comparison of plasma exchange procedures using three apheresis systems

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Double Filtration Plasmapheresis for Children with Different Types of Critical Kidney Diseases: a Single-Center Retrospective Cohort Study

Efficacy of Albumin and Compounded Plasma for Plasma Exchange in Acquired Thrombotic Thrombocytopenic Purpura

Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensity-score matched study from AARC